Co-occurrence of bacteria and viruses and serotype distribution of Streptococcus pneumoniae in the nasopharynx of Tanzanian children below 2 years of age following introduction of the PCV13

Front Public Health. 2024 Jan 22:12:1298222. doi: 10.3389/fpubh.2024.1298222. eCollection 2024.

Abstract

Introduction: Pneumococcal conjugate vaccines have reduced severe disease attributed to vaccine-type pneumococci in children. However, the effect is dependent on serotype distribution in the population and disease development may be influenced by co-occurrence of viral and bacterial pathogens in the nasopharynx.

Methods: Following introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) in Tanzania we performed repeated cross-sectional surveys, including 775 children below 2 years of age attending primary healthcare centers. All children were sampled from nasopharynx and pneumococci were detected by single-target PCR. Pneumococcal serotypes/groups and presence of viruses and other bacteria were determined by two multiplex PCR assays.

Results: The prevalence of PCV13 vaccine-type pneumococci decreased by 50%, but residual vaccine-types were still detected in 21% of the children 2 years after PCV13 introduction. An increase in the non-vaccine-type 15 BC was observed. Pneumococci were often co-occurring with Haemophilus influenzae, and detection of rhino/enterovirus was associated with higher pneumococcal load.

Discussion: We conclude that presence of residual vaccine-type and emerging non-vaccine-type pneumococci in Tanzanian children demand continued pneumococcal surveillance. High co-occurrence of viral and bacterial pathogens may contribute to the disease burden and indicate the need of multiple public health interventions to improve child health in Tanzania.

Keywords: Streptococcus pneumoniae; infant; pneumococcal conjugate vaccines; sub-Saharan Africa; viruses.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carrier State / epidemiology
  • Child
  • Cross-Sectional Studies
  • Humans
  • Nasopharynx
  • Pneumococcal Infections* / epidemiology
  • Pneumococcal Infections* / microbiology
  • Pneumococcal Infections* / prevention & control
  • Pneumococcal Vaccines
  • Serogroup
  • Streptococcus pneumoniae
  • Tanzania / epidemiology
  • Viruses*

Substances

  • Pneumococcal Vaccines

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by the Sahlgrenska Academy, University of Gothenburg and the Swedish International Development Cooperation Agency through provision of the Minor Field Study scholarship. The molecular analysis was funded by research grants from Laboratory Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden. The funding body had no role in the design of the study, the collection, analysis, interpretation of data nor in the writing of the manuscript.